Table 2 Summary of miRNA expression studies on prostate tumor/serum samples

let-7a-2,let-7i,16-1,17-5p,20a,21,24-1,25,27a,29a,29b-2,30c,32, 34a,92-2,93-1,95,101-1, 106a, 124a-1,126a-1,135-2,146,149, 181b-1,184,187,191,196-1 197,199a-1, 214,128a, 195,198, 199a-1,199a-2,203,206,214,218-2,223,

up

tumor

Volina, 2006 [45]

202,210,296,320,370,373*,498,503

up

tumor

Porkka, 2007 [87]

let-7i,25,26a-1/2,31,32,34b,92-1/2,93,99b,106b,125a,181a-1/2,182,188,194-1/2,196a/2,200c, 370, 375,425,449

up

tumor

Ambs, 2008 [40]

221,222

up

tumor

Mercatelli, 2008 [42]

16,19b,24,100,125b,141,143,296

up

serum

Mitchell, 2008 [35]

141,200b, 200c

up

prostate cells

Mitchell, 2008 [35]

221

up

PCa cells

Mercatelli, 2008 [42]

221

up

tumor

Spahn, 2009 [91]

9*,15a,16,145,221,222,331,551a

up

PCa cells

Wang, 2009 [90]

128

up

PCa cells

Khan, 2010 [88]

let-7a,let-7c,let-7f,15b,20a,21,25,26b,30b,106a, 106b, 126*,148a,200c,218,375,

up

tumor

Szczyrba, 2010 [61]

25,93,106b

up

tumor

Poliseno, 2010 [61]

96,182,182*,183

up

tumor

Schaefer, 2010 [81]

141

up

plasma

Gonzales, 2011 [133]

182

up

Prostate cells

Mihelich, 2011 [98]

100,145,191,let7c

up

tumor

Leite, 2011 [138]

9*,141,200b,375,516a-3p

up

serum

Brase, 2011 [115]

21

up

plasma

Yaman Agaoglu, 2011 [54]

34c

up

PCa cells

Hao, 2011 [95]

20a,21,221

up

plasma

Shen, 2012 [56]

107,141,301a,326,432,484,574-3p,625*,2110

up

plasma

Bryant, 2012 [117]

21

up

tumor

Li, 2012 [55]

let-7b,7,9*,17,19b,20a,21,25,30d,32,92a-1*,93,95,96,106a*,106b, 106b*,130b,142-3p,141*, 148a, 153,182,182*,183,183*,200b*, 200c*, 210,301b,363,375,425,512-3p,583,615-3p,663,801,

up

tumor

Martens-Uzunova, 2012 [48]

let-7a,20a,21,106a,106b,375,

up

tumor

Wach, 2012 [10]

96,124,141,302b,375,378*,489,520d-5p,548a-3p,548c-3p, 875-5p,892b,

up

serum

Nguyen, 2013 [116]

96-5p,183-3p,183-5p

up

tumor

Larne, 2013 [108]

10b,15a,15b,16,18a,18b,20b,25,30c,32,34a,34c-5p, 92a, 122, 124,125a-5p,125b,128a,133b, 134, 135b,146b-5p,148b,181a,181b,181c,184,193a-5p,193b,206,214, 215,301a,372

up

tumor

Walter, 2013 [110]

19a,188-5p,574-5p,663,939,1224-5p,1225-5p,1249,1915,K12-3,UL70-3p,

up

tumor

He, 2013 [134]

21

up

tumor

Amankwah, 2013 [102]

32,106b-25,375

up

tumor

Hudson, 2013 [53]

96-5p,182-5p,183-5p,

up

tumor

Tsuchiyama, 2013 [106]

141,200a,200c,210,375

up

serum

Cheng, 2013 [120]

19a,19b,20a,20b,26a,26b,29c,106a,125a,125b,135a, 141, 148a,151–5p,174b,193a, 196b, 331-3p,365, 374a, 374b, 1274b,

up

tumor

Lichner, 2013 [135]

19b

up

tumor

Wang, 2014 [124]

182,SNORD78,U17b,U78_s,U78_x

up

tumor

Casanova-Salas 2014 [111]

17*,200b*,210,297,375,501-3p,551b,562

up

serum

Haldrup, 2014 [113]

345,519c-5p

up

serum

Wang, 2014 [124]

93,106b-25

up

PCa cells

Liang, 2014 [61]

Let-7a,103,107,130b,106a,26b,451,223,93,24,30c,874,100, 146a

up

serum

Mihelich, 2015 [125]

let-7a-5p,let-7d-3p,let-7d-5p,7-5p,7b-5p,20a-5p,21-3p,25-3p, 29b-2-5p,30d-3p,92a-3p, 92b-3p, 93-3p,96-5p,103a-3p,107, 130b-3p, 182-5p,183-5p,191-5p,196b-5p,200b-3p, 200b-5p, 200c-3p 329, 331-3p,339-3p,342-5p,375,421,423-3p,423-5p, 425-5p, 484, 615-3p,663a,663b,664a-3p, 1248,1260a

up

tumor

Kristensen, 2016 [112]

Let-7a,let-7b,let-7c,let-7d,let-7 g,16,23a,23b,26a,92,99a,103,125a,125b,143,145,195,199a, 199a*,221,222,497

down

tumor

Porkka, 2007 [87]

let-7b,1-2,34a,145,7-1/2,126,128a,133a-1,145,205,218-2,220,221,329,340,345,410, 487,490,494,499,520 h

down

tumor

Ambs, 2008 [40]

let-7b-g, 26a-b,29a-c,30a-e,99a-b,125a-b,145, 200a-b

down

tumor

Ozen, 2008 [79]

22,24,27a,27b,29a,30e,101,125a-5p,125b,143, 145, 152, 199a-5p,221,223,320,424,

down

tumor

Szczyrba, 2010 [61]

16,31,125b,145,149,181b,184,205,221,222

down

tumor

Schaefer, 2010 [81]

34c

down

tumor

Hagman, 2010 [92]

34c

down

PCa cells

Hao, 2011 [95]

30c,100,223,346

down

Prostate cells

Mihelich, 2011 [98]

141

down

plasma

Yaman Agaoglu, 2011 [54]

143,145,221

down

tumor

Wach, 2012 [10]

1,15a,16-1,133a

down

tumor

Kojima, 2012 [52]

1,10b,27b,29a,29b,34b,126,126*,130a,133a,133b,139-5p,142-3p,142-5p,143,143*,145,145*, 146a,149,150,155,181b,193b,193b*,204,205,221,221*,222,223,224,328,338-3p, 342-5p, 361-3p 378,378*,455-3p,455-5p,483-3p,485-3p,551b

down

tumor

Martens-Uzunova, 2012 [48]

181a-2*

down

plasma

Bryant, 2012 [117]

31-5p,34c-5p,205-5p,221-3p,222-3p

down

tumor

Tsuchiyama, 2013 [106]

101

down

tumor

Hudson, 2013 [49]

221,222

down

tumor

Amankwah, 2013 [102]

23b,26b,30c,155,181d,193a-5p,200b-5p,205,221,221-5p,222,224,335,374a,374b, 455-3p,505

down

tumor

He, 2013 [134]

145-5p,205-5p,221-5p,409-5p

down

tumor

Larne, 2013 [108]

224

down

tumor

Mavridis, 2013 [109]

222

down

serum

Cheng, 2013 [120]

409-3p,623,

down

serum

Nguyen, 2013 [116]

19a,19b

down

serum

Wang, 2014 [124]

34a*,34c-3p,187,221*,221,224,

down

tumor

Casanova-Salas 2014 [111]

1,133b

down

tumor

Karatas, 2014 [55]

1

down

Prostate cells

Chang, 2015 [46]

15a-5p,16-5p,19b-3p,22-3p,23a-3p,23b-3p,24-3p,26a-5p, 27a-3p, 27b-3p,29a-3p, 29b-3p,30a-3p,30a-5p,30c-5p,30e-3p, 30e-5p, 33a-5p,34a-5p,99a-3p,99a-5p,101-3p, 125b-2-3p, 125b-5p, 127-3p,130a-3p,132-3p,136-5p,143-3p,149-5p, 152, 154-5p,155-5p, 181a-5p,181b-5p,195-5p, 199a-3p,199a-5p, 199b-5p,205-5p, 214-5p,218-5p,221-3p,222-3p, 223-3p,335-5p,338-3p,362-3p,363-3p376a-3p,376c-3p,424-5p, 451a,455-3p, 455-5p,497-5p,502-3p,660-5p

down

tumor

Kristensen, 2016 [112]